research report, 'Probiotics Market (2009 -2014 ' the global probiotics market generated US $15.9 billion in 2008 and is expected to be worth US $ 32.6 billion by 2014 with a compound annual growth rate of 12.6 per cent from 2009 to 2014 2 . The probiotic product industry in India is an estimated ` 20.6 million with a projected annual growth rate of 22.6 per cent until 2015 3 .
There are no regulatory guidelines for probiotic foods in India. Hence, there would always be a possibility of spurious and ineffective products with false claims being marketed. Hence, it becomes imperative that these products are standardized to fulfi ll some essential prerequisite conditions before being labelled as a 'probiotic product'.
A Task Force was, therefore, constituted by the ICMR, comprising experts from varied fi elds to draft guidelines for evaluation of probiotics in India. The Task Force took into consideration the guidelines available in different parts of the world 4-10 and deliberated on the various aspects to be covered [11] [12] [13] [14] [15] . The following guidelines have been drafted for scientifi c purpose for evaluating probiotics foods. The guidelines hereafter will be known as "ICMR-DBT guidelines". The current molecular techniques used for identifi cation include PCR based techniques, 16S rRNA sequencing and DNA fi ngerprinting techniques like ribotyping and pulsed fi eld gel electrophoresis (PFGE).
ICMR-DBT Guidelines for Evaluation of Probiotics
It is recommended that probiotic strains in use in India should be deposited in an internationally recognized culture collection/repository.
In vitro tests to screen potential probiotic strains:
The following in vitro tests * with standard methodology are recommended for screening putative probiotic strains:
(i) Resistance to gastric acidity, (ii) Bile acid resistance, (iii) Antimicrobial activity against potentially pathogenic bacteria (acid and bacteriocin production), (iv) Ability to reduce pathogen adhesion to surfaces, (v) Bile salt hydrolase activity. * Adherence to mucus and/or human epithelial cells and cell lines has in the past been used to screen candidate probiotics. The Committee debated this and concluded that there are probiotics which are not adherent. Hence this should not be used as a mandatory criterion or to claim superiority of one strain over another in terms of probiotic attributes and functionality. These tests are based on the hostile gut environment which these mimic under in vitro conditions. The cultures evaluated as probiotics based on these tests should be subjected to preclinical validation in appropriate animal models before clinical trials are conducted in human subjects.
5.
In vivo safety studies in animal models: Assessment of the acute, subacute and chronic toxicity of ingestion of extremely large amounts of probiotics should be carried out for all potential strains. Such assessment may not be necessary for strains with established documented use.
In vivo effi cacy studies in animal models:
To substantiate in vitro effects, appropriate, validated animal models must be used fi rst, prior to human trials.
Evaluation of safety of probiotics for human use:
In recognition of the importance of assuring safety, even among group of bacteria that are Generally Recognized as Safe (GRAS) ** , probiotics strains needs to be characterized at a minimum with the following tests:
(i) Determination of antibiotic resistance patterns. It should be ascertained that any given probiotic strain is not at signifi cant risk with regard to transferable antibiotic resistance.
(ii) Assessment of undesirable side-effects.
(iii) If the strain under evaluation belongs to a species that is a known mammalian toxin producer or of haemolytic potential, it must be tested for toxin production and haemolytic activity respectively. Assessment of lack of infectivity by a probiotic strain in immunocompromised individuals would be an added measure.
Evaluation of effi cacy studies in humans:
The principal outcome of effi cacy studies on probiotics should be proven with similar benefi ts in human trials, such as statistically and clinically signifi cant improvement in condition, symptoms, signs, well-being or quality of life, reduced risk of disease or longer time to next occurrence or faster recovery from illness. Each of the parameter should have proven correlation with the probiotics tested.
Probiotics delivered in food may not be tested in Phase 3 studies (effectiveness), unless the product makes a specifi c health claim wherein it becomes imperative to generate the required evidence necessitating carrying out Phase 3 studies.
If a probiotic food has a record of documented long and safe use outside the country, the data regarding this could be reviewed and deemed as suffi cient to allow its marketing within the country. However, labeling of health benefi ts may require evaluation in a different manner. While taking into account studies done abroad, effi cacy studies of probiotics (which are of proven benefi t in 'other' populations) should also be conducted on Indian subjects. It is recommended that such 'bridging' human trials should comply with the principles laid down by the Drug Regulatory Authority. Adverse effects, if any, should be monitored and incidents reported to the appropriate authority.
9. Effective dosage of probiotic strain/strains: The minimal effective dose or the level of viable cells of the probiotic strain in terms of cfu/ml/day in the carrier food that demonstrates general health promoting functions or well being or specifi c health claims in target population should be clearly indicated.
Labeling requirements:
In addition to the general labeling requirements under the food laws, the following information should also be mentioned on the label 18, 19 .
(i) Genus, species and strain designation following the standard international nomenclature.
(ii) The minimum viable numbers of each probiotic strain should be specifi ed at the level at which effi cacy is claimed and at the end of shelf-life.
(iii) Evidence-based health claim(s) should be clearly stated.
(iv) The suggested serving size to deliver the minimum effective quantity of the probiotic related to the health claim.
(v) Proper storage conditions to be mentioned.
Manufacturing and handling procedures:
Adequate quality assurance programmes should be in place. Good Manufacturing Practices should be followed in the manufacture of probiotic foods. 
